Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : OECD chief says IP rights on vaccines not main issue in COVID-19 fight

06/01/2021 | 10:46am EDT

PARIS, June 1 (Reuters) - The suspension of intellectual property rights on COVID-19 vaccines is not the main challenge in the race to get vaccines distributed around the world, new OECD Secretary-General Mathias Cormann said on Tuesday.

Asked whether an Organisation for Economic Cooperation and Development ministerial council meeting had discussed the possibility of suspending pharmaceutical companies' IP rights on coronavirus vaccines they had developed, Cormann told reporters that there were other priorities

"In terms of how best to ensure that we can guarantee a rollout of the vaccines on a worldwide basis, there are many issues that are more important ... and in particular making sure that we have effective production and distribution mechanisms in place," Cormann said.

Earlier this month, U.S. President Joe Biden threw his support behind waiving intellectual property rights for COVID-19 vaccines, bowing to mounting pressure from Democratic lawmakers and more than 100 other countries, but angering pharmaceutical companies.

The World Trade Organization (WTO) held talks this week about an intellectual property waiver for COVID-19 vaccines but there has been little progress towards a possible deal, despite Washington's backing for the idea. (Reporting by GV De Clercq; editing by Jonathan Oatis)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.50% 8996 Delayed Quote.22.83%
PFIZER LIMITED -1.11% 5157 End-of-day quote.0.97%
All news about ASTRAZENECA PLC
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22European ADRs Move Higher in Friday Trading
MT
10/22ASTRAZENECA : COVID-19 Jab Safe for Pregnant Women, No Impact on Fertility
MT
10/21VC DAILY : ShouTi Lands $100 Million to Develop -2-
DJ
10/21ASTRAZENECA : Puts Cancer Drug Trial On Hold Due To Safety Concerns
MT
10/21ASTRAZENECA : JP Morgan reaffirms its Buy rating
MD
10/20ASTRAZENECA : Credit Suisse remains its Buy rating
MD
10/20ASTRAZENECA : Announces Winners and Recognizes Oncology Change Makers in Third Annual Canc..
BU
10/20ASTRAZENECA : Air Malta Transports Maltese Solidarity to Rwanda; 135,690 AstraZeneca vacci..
AQ
10/20KAROLINSKA INSTITUTET : Two COVID-19 Vaccine Doses Increase Airway Antibodies After Infect..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 441 M - -
Net income 2021 4 862 M - -
Net Debt 2021 24 847 M - -
P/E ratio 2021 35,8x
Yield 2021 2,28%
Capitalization 192 B 192 B -
EV / Sales 2021 6,11x
EV / Sales 2022 4,94x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 123,70 $
Average target price 137,80 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC22.83%191 835
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979